FibroGen has revealed that a second late-stage clinical trial of Duchenne muscular dystrophy (DMD) therapy pamrevlumab has failed to show efficacy, extending a run of bad
Swiss biotech Alentis Therapeutics has raised a very respectable $105 million in third-round financing that will be dedicated to the development of its Claudin-targeting d
Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist.